(5-phenyl-3-isoxazolyl)-(1-pyrrolidinyl)methanone is a chemical compound, also known by its more common name **ISX-9**. It is a **potent and selective inhibitor of the enzyme histone deacetylase 6 (HDAC6)**.
**What is HDAC6?**
HDAC6 is an enzyme that plays a crucial role in regulating the acetylation of proteins, a process that is involved in various cellular functions, including cell growth, differentiation, and stress response.
**How does ISX-9 work?**
ISX-9 specifically binds to and inhibits HDAC6, preventing it from removing acetyl groups from proteins. This leads to an accumulation of acetylated proteins, which can have a number of effects on cellular processes.
**Why is ISX-9 important for research?**
ISX-9 has shown promising therapeutic potential in various research settings, including:
* **Cancer research:** By inhibiting HDAC6, ISX-9 can induce cell death in cancer cells and inhibit tumor growth.
* **Neurodegenerative disease research:** HDAC6 is implicated in the progression of neurodegenerative diseases like Alzheimer's and Parkinson's. ISX-9 might be useful in protecting against neuronal damage and improving cognitive function.
* **Inflammation research:** HDAC6 is involved in regulating inflammation. ISX-9 may be beneficial in treating inflammatory conditions.
* **Other areas:** Research is ongoing to explore ISX-9's potential in other areas such as wound healing and heart disease.
**Important Notes:**
* ISX-9 is currently **not approved for clinical use** in humans.
* The research on ISX-9 is ongoing, and further studies are needed to understand its full potential and any potential side effects.
**In summary,** (5-phenyl-3-isoxazolyl)-(1-pyrrolidinyl)methanone (ISX-9) is a powerful research tool that offers potential for treating various diseases by targeting the enzyme HDAC6.
ID Source | ID |
---|---|
PubMed CID | 973874 |
CHEMBL ID | 1408325 |
CHEBI ID | 109085 |
Synonym |
---|
SDCCGMLS-0018553.P002 |
TIMTEC1_008361 |
MLS000064968 |
smr000078290 |
5-phenyl-3-(1-pyrrolidinylcarbonyl)isoxazole |
CHEBI:109085 |
HMS1557M01 |
(5-phenyl-1,2-oxazol-3-yl)-pyrrolidin-1-ylmethanone |
AKOS000559506 |
HMS2478D21 |
(5-phenyl-1,2-oxazol-3-yl)(pyrrolidin-1-yl)methanone |
STL176908 |
5-phenyl-3-[(pyrrolidin-1-yl)carbonyl]-1,2-oxazole |
JDBDMIPWPHEKEQ-UHFFFAOYSA-N |
CHEMBL1408325 |
Q27188122 |
(5-phenyl-3-isoxazolyl)-(1-pyrrolidinyl)methanone |
(5-phenyl-3-isoxazolyl)(1-pyrrolidinyl)methanone |
Class | Description |
---|---|
heteroarene | A heterocyclic compound formally derived from an arene by replacement of one or more methine (-C=) and/or vinylene (-CH=CH-) groups by trivalent or divalent heteroatoms, respectively, in such a way as to maintain the continuous pi-electron system characteristic of aromatic systems and a number of out-of-plane pi-electrons corresponding to the Hueckel rule (4n+2). |
aromatic amide | An amide in which the amide linkage is bonded directly to an aromatic system. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 9.5283 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 4.9178 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
P53 | Homo sapiens (human) | Potency | 79.4328 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 0.7943 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 14.1254 | 0.0018 | 15.6638 | 39.8107 | AID894 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 1.0323 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 12.5893 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 0.8913 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 11.2202 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |